Preclinical Models for Assessment of Antidepressant Abuse Potential
| Autor: | Blake A. Hutsell, Matthew F. Lazenka |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Urology Obstetrics and Gynecology Anhedonia medicine.disease 030227 psychiatry Substance abuse 03 medical and health sciences 0302 clinical medicine Monoamine neurotransmitter Sexual dysfunction medicine Abuse liability Antidepressant medicine.symptom Psychology Psychiatry 030217 neurology & neurosurgery Extracellular dopamine Depression (differential diagnoses) Clinical psychology |
| Zdroj: | Current Sexual Health Reports. 9:241-250 |
| ISSN: | 1548-3592 1548-3584 |
| DOI: | 10.1007/s11930-017-0128-z |
| Popis: | This review considers the contribution of monoamine neurotransmitters to anhedonia, substance abuse, and sexual dysfunction and the relationship between antidepressant efficacy and abuse liability. The use of drugs with known abuse potential to treat depression, the addition of psychostimulants with antidepressants, and the development of novel antidepressants with preclinical evidence for abuse liability have increased in recent years. This is in contrast to the general lack of abuse potential reported for traditional antidepressants such as selective serotonin reuptake inhibitors. While these new strategies might have the benefit of reduced sexual dysfunction, it is at the expense of increased abuse liability. Increasing extracellular dopamine may both increase antidepressant efficacy and reduce sexual dysfunction, but it increases abuse potential. Preclinical researchers should incorporate behavioral economics to assess both antidepressant efficacy and abuse liability while clinicians need to be aware of this relationship in considering novel treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink